Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors

NCT05875168 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT05875168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05875168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 18, 2023
Completion date
February 15, 2027
Enrollment
590 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor